If you or someone you love has been diagnosed with cancer, the amount of information coming at you can feel like too much. Here is one number worth holding onto: for people diagnosed between 2015 and 2021, 5 year survival across all cancers combined reached 70%. That has never happened before in US history. In the mid 1990s the same figure was 63%, and for metastatic cancer it has doubled, from 17% to 35%.
That progress did not come from one miracle drug. It came from thousands of clinical trials, run one at a time, over decades. This article walks through what cancer treatment actually looks like today, what researchers are testing right now, and why the pace of progress depends on something most people never think about: whether patients join studies at all.
Looking for treatment options for cancer?
Browse open Oncology clinical trials near you! We'll handle the follow-up.
What are the main cancer treatment options today?
Cancer is not one disease, it is more than 100. So there is no single "cancer treatment." What exists instead is a toolbox, and doctors combine tools based on the cancer type, its stage, and increasingly, the specific mutations inside the tumor. The main tools:
Surgery. The oldest tool and still one of the most effective for cancer that has not spread. The surgeon removes the tumor and often some tissue around it.
Radiation therapy. High energy beams that damage cancer cells in a targeted area. About half of all cancer patients receive radiation at some point in their care.
Chemotherapy. Medicines that kill fast dividing cells throughout the body. Chemo is why treatment reaches cancer cells that have broken away from the original tumor. It also affects healthy fast dividing cells, which is where many of its side effects come from.
Targeted therapy. Drugs designed against one specific molecular change that a tumor depends on. This is the fastest growing category: of the 16 new cancer drugs the FDA approved in 2025, nearly half were kinase inhibitors, pills that block one specific growth signal. These drugs usually require a tumor test first, because they only work if your cancer carries the target.
Immunotherapy. Treatments that help your own immune system recognize and attack cancer. More on this below, because it changed the field.
Hormone therapy, stem cell transplant, and others. Some cancers, like many breast and prostate cancers, grow in response to hormones, and blocking those hormones slows the disease. Blood cancers like leukemia and lymphoma sometimes call for a stem cell transplant.
One more thing that surprises people: cancer is now the busiest area of drug development in medicine. Cancer medicines accounted for about 35% of all new FDA drug approvals in 2025. In the last three months of 2025 alone, the FDA issued 20 oncology approvals.
What is immunotherapy for cancer?
Immunotherapy is treatment that works on your immune system instead of attacking the tumor directly. Your immune system already knows how to destroy abnormal cells. The problem is that cancer cells learn to hide from it, sometimes by switching on "brakes" that tell immune cells to stand down.
The best known immunotherapies, called checkpoint inhibitors, release those brakes. Drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo) started out in advanced melanoma and lung cancer and are now approved across dozens of cancer types, increasingly at earlier stages of disease rather than as a last resort.
Then there is CAR T cell therapy, which goes a step further. Doctors collect a patient's own immune T cells, re engineer them in a lab to recognize the cancer, and return them to the body. CAR T started in blood cancers, and its reach keeps growing: in December 2025 the FDA approved a CAR T therapy (Breyanzi) for marginal zone lymphoma, bringing this approach into slower growing lymphomas for the first time.
A newer wave, bispecific antibodies, works like a matchmaker: one arm of the drug grabs a cancer cell, the other arm grabs an immune T cell, and it physically pulls them together so the immune cell can do its job.
Immunotherapy does not work for every person or every cancer, and researchers still cannot fully predict who will respond. That question, who responds and why, is one of the most active areas in all of cancer research.
What researchers are studying now
The scale of cancer research is unlike any other field. Close to 19,000 cancer studies are recruiting worldwide right now, about 7,000 of them in the US. A few directions stand out.
Moving the best drugs earlier. Many current trials test whether treatments that work in advanced cancer help more when given sooner, before or right after surgery. In March 2026 the FDA approved an immunotherapy combination for previously untreated advanced Hodgkin lymphoma, part of a broader shift from "last resort" to "first line."
Antibody drug conjugates. These are targeted missiles: an antibody finds the cancer cell, and a chemotherapy payload attached to it is released only there. Two new ones were approved in 2025, and dozens more are in trials.
Precision oncology. More and more trials enroll by mutation rather than by body part. A lung cancer trial may accept only patients whose tumor carries one specific gene change, like KRAS G12C. This makes drugs more effective for the right patients, and it is also why tumor testing has become a normal part of cancer care.
Cancer vaccines. Not to prevent cancer, but to treat it: teaching the immune system what the patient's specific tumor looks like. Most of this work is in early stages, and it is one of the most watched corners of the pipeline.
A few examples of what is recruiting right now on our platform show the range: a Genentech study testing a new targeted drug in advanced solid tumors, a large Phase 3 breast cancer trial combining a targeted pill with an approved antibody treatment in a specific mutation group, and a lung cancer study that selects participants by biomarker before surgery.
Why cancer research takes time
With this much money and effort, why does a new treatment still take years to reach patients? A few named problems.
The participation problem. This is the big one. Fewer than 1 in 10 adult cancer patients joins a treatment trial. The most recent national estimate puts it at about 7%, and for decades it sat between 2% and 8%. It is not because people refuse: when patients are actually offered a trial, more than half say yes. The real barriers sit upstream. For more than half of US patients, no suitable trial exists where they get their care, and most Americans receive cancer care at community clinics rather than big academic centers where trials concentrate. Slow enrollment delays results, and 20 to 40% of cancer trials never finish because they cannot find enough participants.
The children's lesson. Here is what higher participation buys. More than half of children with cancer are treated within a clinical trial, the highest rate in all of medicine. Childhood cancer mortality started falling in the 1970s, two decades before adult cancer mortality began to drop. A research system that enrolls more patients produces progress faster. Adults have never come close to that participation rate.
The 100 diseases problem. Because cancer is many diseases, every treatment has to be tested type by type, stage by stage, and now mutation by mutation. Precision oncology makes drugs better and trials harder at the same time: when a study needs patients with one rare mutation, finding enough of them takes years.
The representation problem. Cancer does not affect all communities equally, but trial participants have not historically reflected the people who actually get cancer. Black and Hispanic patients, older adults, and rural patients remain underrepresented, which makes results less certain for exactly those groups. Many current studies name diverse enrollment as a goal, and decentralized trials that come to the patient are part of the answer. Here's why diversity in clinical trials matters so much.
Common myths about cancer treatment and trials
"A clinical trial means getting a placebo instead of treatment."
This is the most damaging myth in oncology. In cancer treatment trials, the comparison group receives the current standard treatment, not a sugar pill. Placebos, when used at all, are usually added on top of standard care. Leaving a cancer patient untreated would be unethical, and trial rules reflect that.
"Trials are only a last resort."
Not anymore. There are trials for newly diagnosed patients, for prevention, for early stage disease, for survivors dealing with side effects. Some of the biggest recent advances came from testing treatments earlier, not later.
"There is a hidden cure."
No. Progress in cancer is real, public, and incremental: a 34% drop in the death rate since 1991 came from thousands of published studies, not from any single breakthrough. An estimated 4.8 million US cancer deaths have been averted over that period.
"Cancer treatment means chemotherapy."
Chemo is one tool of five or more, and for some cancers it is no longer the main one. Many patients today receive targeted pills or immunotherapy with no traditional chemotherapy at all.
How cancer stages shape treatment
Most solid tumors are staged 0 to IV using the TNM system: tumor size (T), lymph node involvement (N), and metastasis (M). Treatment usually tracks the stage. Early stage cancer is often treated with surgery or radiation alone. Regional disease commonly adds drug treatment before or after surgery. Stage IV, metastatic cancer, is usually treated with body wide therapies: chemo, targeted drugs, immunotherapy, or combinations. Blood cancers use their own systems entirely.
This is a description of typical practice, not a recommendation. Your plan depends on your exact diagnosis and belongs to you and your oncology team.
For trials, the stage is often the headline. Study titles say "resectable," "locally advanced," or "metastatic" right up front, so knowing your stage lets you filter studies in seconds. And stage IV does not shut the door: much of today's most active research, from immunotherapy combinations to antibody drug conjugates, is built specifically for metastatic disease.
How to find a cancer clinical trial
AllClinicalTrials.com lists thousands of oncology studies recruiting across the US, searchable by cancer type, stage, and location. A couple of examples recruiting right now: a Phase 3 trial combining the targeted pill inavolisib with the antibody combination Phesgo for PIK3CA-mutated, HER2-positive metastatic breast cancer, and a biomarker-selected trial for resectable stage IB-III non-small cell lung cancer that screens by mutation before surgery.
The application takes about 5 minutes: you answer questions about your diagnosis and treatment history, and if a study near you looks like a match, the research team contacts you. Nothing is decided until you have gone through informed consent, and participation is voluntary at every step. Some studies offer compensation for time and travel, which is always explained before you agree to anything.
It helps to have three things ready before you start: your exact diagnosis (cancer type and stage), your treatment history, and any tumor biomarker results if you have had testing. Those three answers decide eligibility for most cancer studies.
Common questions
What are the 5 main types of cancer treatment? Surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Hormone therapy and stem cell transplant are also standard tools for specific cancers. Most patients receive a combination rather than a single treatment.
What is the newest treatment for cancer? The most active new areas are immunotherapy (including CAR T cells and bispecific antibodies), antibody drug conjugates, and targeted pills matched to tumor mutations. The FDA approved 16 new cancer medicines in 2025 alone, so "newest" changes almost monthly.
Is cancer treatment better than it used to be? Measurably. Five year survival for all cancers combined rose from 63% in the mid 1990s to 70% for people diagnosed in 2015 to 2021, and survival in metastatic disease doubled over the same period. The gains were largest in some of the deadliest cancers: myeloma survival went from 32% to 62%, and liver cancer from 7% to 22%.
Do I have to stop my current treatment to join a trial? Not necessarily. Some trials add a study drug to your current treatment, others enroll people whose current treatment stopped working. Each study describes this in its eligibility criteria, and the study team walks you through it before anything changes.
See cancer clinical trials recruiting now
Browse open oncology studies, filter by cancer type and location, and apply in about 5 minutes: Oncology Clinical Trials